Trials / Terminated
TerminatedNCT02355574
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 301 (actual)
- Sponsor
- Castle Biosciences Incorporated · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The INTEGRATE Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed. Data will be collected through review of medical records from clinical visits with physician. The purpose is to document the clinical application of results obtained from the DecisionDx- Melanoma multi-gene assay and to track outcomes of patients for whom DecisionDx-Melanoma testing has been completed. Additionally the study will assess the health economic impact of DecisionDx-Melanoma testing as it relates to the Melanoma population.
Conditions
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2021-02-01
- Completion
- 2021-07-01
- First posted
- 2015-02-04
- Last updated
- 2021-10-08
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02355574. Inclusion in this directory is not an endorsement.